FlaggedRx Supplier Risk Check
Live cross-regulator supplier-flag monitoring

Know your supplier was flagged. Weeks before the warning letter.

On Jan 22, 2026, Flowchem Pharma landed on FDA's Import Alert 66-40 Red List — its products detained at the US border. The warning letter didn't publish until Mar 11. That ~7-week gap is the product: FlaggedRx is the cross-regulator early-warning feed that tells your Quality team the day a foreign API or CMO supplier is flagged, while the market waits on the press release.

Public, non-personal regulatory data · provenance & freshness on every record · decision-support, not a safety verdict.
462
firms on FDA Import Alert 66-40 (the Red List), tracked live
107
India-based — across 55 countries on one watch surface
9
newly flagged in the last 45 days
~7 wks
Flowchem's head start: Red List Jan 22 → warning letter Mar 11, 2026

Live coverage across 6 regulator sources in 4 jurisdictions — every flag verified at the source, with provenance and freshness on each record.

FDAImport Alert 66-40
🇺🇸 US · Red List
FDADrug recalls
🇺🇸 US · openFDA
FDAWarning letters
🇺🇸 US · Data Dashboard
FDAImport refusals
🇺🇸 US · Data Dashboard
MHRAAlerts & recalls
🇬🇧 UK · GOV.UK
CDSCONSQ & spurious
🇮🇳 India
How it works

A cross-regulator flag report in seconds — then continuous monitoring

1

Check

Paste a supplier name → every recall, alert, import refusal, and Import Alert 66-40 placement we can find, each with a source link, a freshness date, and a 0–100 risk score.

2

Watch

Add your supplier base to a watchlist. We snapshot, diff, and email you a 🚨 EARLY WARNING the instant a new Red List placement appears. (Slack delivery coming.)

3

Prove

Export the audit CSV — the inspector-ready artifact for your 21 CFR 211 supplier-qualification file, FEI-keyed with provenance.

The event you're insuring against

A 66-40 listing can cost $150M–$500M — before the letter is even public

When a foreign supplier lands on FDA's Import Alert 66-40 Red List, its shipments are detained at the US border without physical exam. The signal exists weeks before the warning letter — it just sits siloed across regulators in incompatible formats. FlaggedRx closes that gap so Quality acts on the border flag, not the press release. We surface flags with provenance and link every one to the authoritative record. A human decides — absence of a flag is never an all-clear.

Jan 22, 2026
Import Alert 66-40 (Red List)
~7 weeks of lead time
Mar 11, 2026
Warning letter published

Real, primary-source-verifiable case: Flowchem Pharma Private Limited (Andhra Pradesh, India). See the 48-day gap measured →

What actually lands in your inbox

One email, the day the border flag appears

No dashboard-watching. When a supplier you monitor hits the Red List — or gets a recall, warning letter, refusal, MHRA or CDSCO flag — this is the alert, with a link to the source record.

From: alerts@flaggedrx.com  ·  Subject: 🚨 1 new supplier flag — action may be needed
FlaggedRx

1 new regulatory flag on your watched suppliers — 1 critical.

  • 🚨 EARLY WARNINGFlowchem Pharma Private Limited added to FDA Import Alert 66-40 (Red List) on 2026-01-22. Shipments detained at the US border now → accessdata.fda.gov/cms_ia
Open your dashboard →

Decision-support from public regulatory data — not a safety verdict. Absence of a flag is not an all-clear.

Live feed

Recently added to the FDA Import Alert 66-40 Red List

Loading the live Red List…

Updated from the live FDA Red List. Search any of these to see the full cross-regulator picture.

The moat

Cross-regulator entity resolution — one supplier, every alias

The hard part isn't fetching data; it's knowing the firm on FDA's Red List is the same one in an MHRA recall and a CDSCO notice, spelled three different ways. FlaggedRx resolves one supplier across transliteration, legal-suffix, and subsidiary variance — "Accord" alone collapses 60+ name variants across FDA and MHRA into a single identity — so a flag filed under a subsidiary or a misspelled legal name still reaches you. We bias toward keeping firms separate over wrongly merging them, and route ambiguous high-severity matches to a human review queue.

Where we fit

The early-warning tripwire — not another enterprise database

Enterprise reg-intelligence platforms are comprehensive and excellent — and quote-only, with 30–90 day procurement. We're complementary: cheap, self-serve, same-day, focused on the one signal your supplier-qualification file lives or dies on. We're additive to your Quality workflow — nothing to rip out.

Enterprise reg-intelWaiting for the warning letterFlaggedRx
Job to be doneComprehensive multi-agency database + workflowSupplier-flag early warning + watchlist matching
Import Alert 66-40 lead timeCovered0 — you learn at publication~7 weeks before the letter
India / CDSCO NSQ coverageVariesIncluded
Cross-regulator identity resolutionYesYes — on the import-alert blind spot
AccessEnterprise quote-only · 30–90 day procurementFree (but too late)Self-serve · same-day
PriceQuote-only (enterprise)$450–$1,500/mo

We don't claim to be the only cross-regulator monitor — enterprise platforms do it too. Our edge is CDSCO/India inclusion, identity resolution on the foreign-supplier import-alert blind spot, and self-serve access. Competitor pricing is not public; we show only our own.

Who it's for

Built for the people who own 21 CFR 211

Quality, Supplier Quality, and RegOps at US generic and specialty pharma makers — and the CDMOs and importers who answer to them. If your first signal that a sourced site was detained at the US border is the published warning letter, you've already lost the weeks that matter. Start free with a single Supplier Risk Check; upgrade to continuous monitoring and audit exports for your whole supplier list.

Is your supplier flagged anywhere?

Run a free cross-regulator Supplier Risk Check — no login.

Check a supplier ↑
Coverage

What we monitor — and how fresh it is

Six regulator feeds across four jurisdictions. Source, cadence, and coverage are stated per row — and on every alert. A feed that goes stale or dark degrades loudly on our live source status; it never silently reads as "no flags found."

SourceWhat we indexCadenceCoverage
FDA — Import Alert 66-40
🇺🇸 Red List (DWPE · cGMP drugs)
Foreign firms detained at the US border — the wedge signal. See the searchable Red List →Continuous · cached ≤12hAll public Red List firms
FDA — Warning Letters
🇺🇸 Data Dashboard
Company · issuing office · subject · FEI join key~weeklyAll public warning letters
FDA — Import Refusals
🇺🇸 Data Dashboard
Per-shipment refusals · firm · FEI~weeklyAll public import refusals
FDA — Drug Recalls
🇺🇸 openFDA enforcement
Recalling firm · class · reason~weeklyAll public US drug recalls
MHRA
🇬🇧 GOV.UK
Class 1–4 medicines recalls · firm · action~dailyUK medicines safety alerts
CDSCO India
🇮🇳 NSQ / spurious
Not-of-standard-quality + spurious-drug alerts · manufacturer — the differentiator~monthlyPublic NSQ / spurious PDFs

Live per-source last-checked status and staleness → source status. Not-of-standard-quality is not approval; absence of a flag is never an all-clear.

FAQ

Questions Quality teams ask first

What is FDA Import Alert 66-40?
The "Red List" of foreign drug firms placed under Detention Without Physical Examination (DWPE) for cGMP problems. Once a firm is listed, its shipments are held at the US border by default — an operational block that takes effect immediately, before any public warning letter.
Why does the Red List placement come ~7 weeks before the warning letter?
The import alert is FDA's operational action; the warning letter is the later public documentation of it. In our verified hero case, Flowchem Pharma was placed on 66-40 on 2026-01-22 and the warning letter didn't publish until 2026-03-11 — a ~48-day head start, primary-source-verifiable from the FDA letter itself.
How do you know one supplier is the same firm across regulators?
Entity resolution: normalize → block → score → confidence-tiered merge, with ambiguous high-severity matches routed to a human review queue. We deliberately bias toward keeping firms separate over wrongly merging them — a false merge that makes you drop a good supplier is a safety hazard too.
Do you tell me a supplier is safe?
No — and we never will. We report the presence or absence of a flag, with provenance, and let a human decide. Absence of a flag is not clearance: it means nothing surfaced across the sources we checked, at the time we checked. That's the one promise an enterprise "intelligence score" structurally can't make.
Where does the data come from?
Public regulator records only — FDA (openFDA, Data Dashboard, accessdata), MHRA (GOV.UK), CDSCO (India). Every claim links to its originating record with a fetch time and a content hash. We respect robots.txt and strip personal data from notices that name individuals.
Is this regulatory or legal advice?
No. FlaggedRx is decision-support that surfaces public flags for your team to act on. It does not replace your 21 CFR 211 supplier-qualification process, your auditors, or legal review — it tells you which supplier to look at first.
Trust & transparency

Four standing commitments

How we source, label, and scope what we sell — the same rules whether you're a paying customer or just running a free check.

🔗 Sources are public

We're a UI on public regulator data, not a proprietary score. Every record links to its originating FDA / MHRA / CDSCO source, with a fetch time and content hash.

⏱ Freshness is disclosed

Every record carries a last-checked date. A feed that goes stale or dark degrades loudly on /health and in alerts — it never silently reads as "no flags."

🚫 We never issue a "safe" verdict

We report the presence or absence of a flag — never "this supplier is clean." Absence of a flag is not an all-clear. A human always decides.

⚖️ Informational, not advisory

Our flags inform your qualification decision. They are not regulatory or legal advice and don't replace your 21 CFR 211 process. See our disclaimer.

Not a pharma buyer — just a patient? Check if your own medication is recalled, in plain language.
Check a medication recall →